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ABSTRACT
Although adjustable transgene expression systems
are considered essential for future therapeutic and
biopharmaceutical manufacturing applications,
the currently available transcription control modal-
ities all require side-effect-prone inducers such
as immunosupressants, hormones and antibiotics
for fine-tuning. We have designed a novel mam-
malian transcription-control system, which is
reversibly fine-tuned by non-toxic vitamin H (also
referred to as biotin). Ligation of vitamin H,
by engineered Escherichia coli biotin ligase (BirA),
to a synthetic biotinylation signal fused to the
tetracycline-dependent transactivator (tTA), enables
heterodimerization of tTA to a streptavidin-linked
transrepressor domain (KRAB), thereby abolishing
tTA-mediated transactivation of specific target
promoters. As heterodimerization of tTA to KRAB
is ultimately conditional upon the presence of
vitamin H, the system is vitamin H responsive.
Transgenic Chinese hamster ovary cells, engineered
for vitamin H-responsive gene expression, showed
high-level, adjustable and reversible production of a
human model glycoprotein in bench-scale culture
systems, bioreactor-based biopharmaceutical man-
ufacturing scenarios, and after implantation into
mice. The vitamin H-responsive expression systems
showed unique band pass filter-like regulation
features characterized by high-level expression at
low (0–2nM biotin), maximum repression at inter-
mediate (100–1000nM biotin), and high-level expres-
sion at increased (`100000nM biotin) biotin
concentrations. Sequential ON-to-OFF-to-ON,
ON-to-OFF and OFF-to-ON expression profiles
with graded expression transitions can all be achie-
ved by simply increasing the level of a single inducer
molecule without exchanging the culture medium.
These novel expression characteristics mediated by
an FDA-licensed inducer may foster advances in
therapeutic cell engineering and manufacturing of
difficult-to-produce protein therapeutics.
INTRODUCTION
Precise transgene expression dosing in mammalian cells
has become a cornerstone for synthetic biology (1–4),
(pre)clinical gene therapy studies (5–8), drug discovery
(9,10), biopharmaceutical manufacturing (11–13) as well
as for numerous applications in functional genomic
research (14–16).
Research and development of inducible mammalian
transgene expression systems has focused on clinically
licensed small-molecule inducers to minimize pleiotropic
side eﬀects in cell culture, animal models or ultimately
in clinical trials (17). Several antibiotics (18–22), steroid
hormone analogs (23–25) and immunosuppressive
substances (26,27) have been successfully used to
modulate transgene expression in vitro and in vivo.
Immunosuppresive drugs such as rapamycin can trigger
transgene expression by conditional heterodimerization
of FKBP, fused to a DNA-binding domain, and FRB,
fused to a transactivation domain, which form a chimeric
transactivor inducing transcription from speciﬁc promo-
ters (26). Steroid hormone-based systems capitalize on the
cytosolic sequestration of nuclear hormone receptors
engineered to contain heterologous DNA binding and
transactivation domains by endogenous heat-shock pro-
tein 90 [Hsp90; (28)]. Addition of steroid hormone analogs
(for example, tamoxifen) displaces Hsp90 which results
in nuclear translocation of the transactivator and induc-
tion of cognate promoters (29,30). Antibiotic-dependent
expression systems [tetracyclines (19), macrolides (21),
streptogramins (18)] take advantage of engineered pro-
karyotic repressors which activate or repress synthetic
target promoters in an antibiotic-responsive manner (17).
The prototype tool for heterologous mammalian gene
regulation is the tetracycline-responsive expression system
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Escherichia coli-derived tetracycline-dependent transacti-
vator (tTA, a fusion of the TetR repressor and the Herpes
simplex VP16 transactivation domain) that binds and
activates tetracycline-responsive promoters (PhCMV  1,
heptameric TetR-speciﬁc operator sites [tetO7] linked to
a minimal version of the human cytomegalovirus immedi-
ate early promoter) (19). In the absence of tetracycline
antibiotics, tTA binds tetO7 and triggers PhCMV  1-driven
transgene expression. In the presence of tetracycline,
tTA-tetO7 binding is abolished and transcription remains
shut down (19). Despite solid regulation characteristics,
ongoing concerns about long-term side eﬀects of anti-
biotics (31,32), as well as the rapid emergence of antibiotic
resistance in bacteria exposed to subclinical environmental
antibiotic concentrations (33), have prevented the use of
the TET systems in gene therapy and biopharmaceutical
manufacturing scenarios. Despite advantages of using
clinically licensed drugs for therapeutic transgene expres-
sion ﬁne-tuning, there are ongoing concerns about side
eﬀects associated with their prolonged administration in
a clinical setting (28,32,34). For example, sustained
administration of immunosuppressive drugs increases the
susceptibility to bacterial infections (35), persistent intake
of steroid hormone analogs may trigger diﬀerent side
eﬀects including pancreatitis (36,37) and continued inges-
tion of antibiotics compromises the intestinal ﬂora (38)
and increases the risk for the emergence of multidrug-
resistant pathogenic bacteria (33). Therefore, the design
of novel transgene control modalities responsive to
side-eﬀect-free trigger molecules remains a current
priority (17,39).
In E. coli synthesis of activated vitamin H (biotin) as
well as biotinylation of target proteins is catalyzed by
the dual-function biotin ligase BirA: (i) BirA activates
biotin (biotinyl-50-adenylate) and transfers the biotin
moiety to an acceptor lysine within a speciﬁc signal
sequence (40). (ii) Furthermore, intracellular biotin con-
centrations are feedback-controlled by biotinyl-50-
adenylate which triggers binding of BirA to a speciﬁc
40bp operator site, thereby inhibiting transcription of the
divergently oriented bioA-BFCD operon and preventing
de novo synthesis of biotin (40). Several synthetic
biotinylation signals have been recently described
[Avitag signal, GLNDIFEAQKIEWHE, target lysine in
bold print, (41)] and used in combination with E. coli BirA
for in vivo and in vitro puriﬁcation of biotinylated target
proteins (42), chromatin immunoprecipitation, as well as
for detection of protein–DNA complexes (43,44).
Capitalizing on the high aﬃnity of biotin to (strept)
avidin [10
 15M; (45)], we have designed a chimeric
transrepressor, which is assembled from tTA-Avitag and
streptavidin-KRAB (krueppel-associated box protein of
the human kox-1 gene) components by biotin-triggered
heterodimerization, and capable of tTA-mediated induc-
tion of PhCMV  1 in a vitamin H-adjustable manner.
Precise transgene expression ﬁne-tuning using a non-toxic
vitamin may represent an important advancement for the
gene therapy and biopharmaceutical manufacturing
communities.
MATERIAL AND METHODS
Vector construction
pWW938 (PSV40-tTA-AT-pA) encoding the tetracycline-
dependent transactivator [tTA; (19)]—Avitag (AT) fusion
(tTA-AT) under the control of the simian virus 40
promoter (PSV40) was constructed by PCR-mediated
ampliﬁcation of the Herpes simplex VP16 transactivation
domain from pWW35 (21) using oligonucleotides
OWW18 (50-GTACGAATTCCCACCatgccccgccccaagct
caa-30, annealing sequence in lower case) and OWW428
(50-GGATCAAGCTTGCGGCCGCTTATTCGTGCCA
TTCGATTTTCTGAGCCGAAGATGTCGTTCAGAC
Ccccaccgtactcgtcaattcc-30, Avitag sequence underlined,
annealing sequence in lower case, HindIII restriction site
in italics) and subsequent ligation of the VP16-AT module
(BssHII/HindIII) into pSAM200 (18). pWW944 (PSV40-
SA-KRAB-pA) encoding streptavidin (SA) fused to the
krueppel-associated box protein of the human kox-1 gene
(KRAB) was constructed by PCR-mediated ampliﬁcation
of streptavidin from pWW801 [PSV40-TetR-SA-pA, PSV40,
simian virus 40 promoter; TetR, tetracycline-dependent
repressor; (39)] using oligonucleotides OWW434
(50-GGATCGAATTCCACCatggctagcatgactggtggac-30,
annealing sequence in lower case, EcoRI restriction site
in italics) and OWW433 (50-GGATCATGCGCGCGGCT
GTACGCGGActgctgaacggcgtcgagc-30, annealing in
lower case, BssHII restriction site in italics) and subse-
quent ligation of the SA module (EcoRI/BssHII) into
pWW43 (21). pWW732 (PhCMV  1-IFN-b-pA) harboring
beta interferon (IFN-b) under the control of the tetra-
cycline-responsive promoter (PhCMV  1) was constructed
by excising IFN-b (EcoRI/HindIII) from pWW430 (46)
and ligating it into pMF111 [PhCMV  1-SEAP-pA, (18)],
thereby replacing SEAP (human placental secreted alka-
line phosphatase). pWW804 (PhCMV-BirA-pA-PSV40-neo
R-
pA, PhCMV, human cytomegalovirus immediate early
promoter; PSV40, simian virus 40 promoter; neo
R, neomy-
cin resistance gene) encoding the E. coli biotin ligase BirA
has been described previously (39), in brief, BirA was
excised (EcoRI/SpeI) from pGEM-SD2 [Strouboulis,J.,
unpublished data, (42)] and ligated (EcoRI/XbaI) into
pMF150 [PhCMV-PIP-pA-PSV40-neoR-pA (18)]. BirA
harbors an N-terminal hemagluttinin (HA) tag. The
triple-transcript vector pTT-Bio [pWW1091, PSV40-SA-
KRAB-PGTX-tTA-AT-PGTX-BirA-pA, PGTX,P GTX, syn-
thetic promoter (47)] was constructed in a three-step
procedure: (i) SA-KRAB excised from pWW944 (EcoRI/
HindIII) was ligated into the corresponding sites of the
ﬁrst multiple cloning site (MCS) of pCF263 [PSV40-MCSI-
PGTX-MCSII-PGTX-MCSIII-pA, (47,48)] resulting in plas-
mid pWW1089. (ii) BirA excised from pWW804 (SpeI/
PmeI) was ligated (SpeI/SwaI) into the third MCS of
pWW1089 resulting in plasmid pWW1090. (iii) Finally,
tTA-AT excised from pWW938 (NotI) was ligated in
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pWW1090 thereby resulting in pTT-Bio.
Cell culture
Wild-type Chinese hamster ovary cells (CHO-K1; ATCC
CCL-61) were cultivated either in biotin-containing or
biotin-free ChoMaster HTS medium (Cell Culture
Technologies, Gravesano, Switzerland) supplemented
with 5% fetal calf serum (FCS, PAN Biotech GmbH,
Aidenbach, Germany, Cat. No. 3302, Lot. No. P231902)
or 10% biotin-free serum replacement (KOSR,
Invitrogen, Carlsbad, CA, USA, cat. no. 10828-028),
respectively, and 1% of a penicillin/streptomycin solution
(Sigma, St. Louis, MO, USA, Cat. No. 4458). Human
embryonic kidney cells [HEK293-T (49)] were cultivated
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) medium
supplemented with 10% FCS or 10% serum replacement
and 1% penicillin/streptomycin solution.
Transfection
All transfection protocols were optimized for a well of a
24-well plate. CHO-K1: 30000 CHO-K1 were seeded 12h
before transfection (0.5ml biotin-free HTS medium
supplemented with 5% FCS). An aliquot of 12ml 0.5M
CaCl2 solution containing 1.2mg total plasmid DNA (for
co-transfections, equal amounts of individual plasmids
were used) were mixed with 12ml phosphate solution
(50mM HEPES, pH 7.05, 280mM NaCl, 1.5mM
Na2HPO4), vortexed for 5s, incubated for 25s at room
temperature to allow formation of the transfection
precipitate and transferred to 0.4ml ChoMaster HTS
medium containing 2% FCS. The culture medium was
replaced by the transfection mixture and the plates were
centrifuged for 5min at 1200 g prior to a 90min
incubation period and a 30s glycerol shock (0.5ml 15%
glycerol in ChoMaster HTS medium containing 2%
FCS). After washing once in 0.5ml biotin-free
ChoMaster HTS medium, the cells were cultivated in
biotin-free or biotin-containing ChoMaster HTS
medium supplemented with 10% KOSR serum replace-
ment or 5% FCS as indicated. HEK293-T: 40000
HEK293-T were seeded 12h before transfection (0.5ml
DMEM, 10% FCS). Twenty microliter of 0.25M CaCl2
containing 0.6mg total DNA (for co-transfections, equal
amounts of individual plasmids were used) were mixed
with 20ml2   HBS solution (100mM HEPES, 280mM
NaCl, 1.5mM Na2HPO4, pH 7.1), incubated for 20min at
room temperature to allow formation of the transfection
precipitate, which was transferred dropwise to the cell
culture and centrifuged onto the cells (5min at 1200 g).
Transfected cells were incubated for 90min at 378C before
they were washed once in FCS-free DMEM and then
cultivated in DMEM containing 10% biotin-free KOSR.
Construction of thestable cell line BioCHO-SEAP
CHO-K1 were ﬁrst co-transfected with plasmids pWW938
(PSV40-tTA-AT-pA), pWW944 (PSV40-SA-KRAB-pA) and
pWW804 (PhCMV-BirA-pA, also carrying a constitutive
expression cassette conferring resistance to G418) at a
ratio of 15:15:1, selected for 12 days in ChoMaster HTS
medium containing 5% FCS and 400mg/ml G418 and
subjected to single-cell cloning. Individual clones, which
functionally express pWW938- and pWW944-encoded
genes, were then co-transfected with pMF111 (PhCMV  1-
SEAP-pA), pWW804 (PhCMV-BirA-pA) and pPUR (con-
ferring constitutive resistance to puromycin; Clontech,
Palo Alto, CA, USA) at a ratio of 15:15:1 followed by
selection for 10 days in ChoMaster HTS medium
containing 5% FCS, 400mg/ml G418 and 15mg/ml
puromycin and single-cell cloning. Individual cell clones
were assessed for biotin-triggered SEAP production and
BioCHO-SEAP1 was chosen for further studies.
Analyticassays
BirA (HA-tagged) and tTA-AT (TetR-VP16-Avitag) were
quantiﬁed by resolving cleared cell lysates on a 10%
SDS–polyacrylamide gel followed by western blot analysis
using anti-HA-tag (Santa Cruz Biotechnology, Santa
Cruz, CA, USA, Cat. No. sc-805) or anti-VP16 (Santa
Cruz, Cat. No. sc-7545) as primary antibodies for
detection and horseradish peroxidase-couple anti-IgG
antibodies for chemiluminescence-based visualization
(ECL plus, GE Healthcare, Piscataway, NJ, USA, Cat.
No RPN2132) with a Chemilux CCD camera (Intas,
Go ¨ ttingen, Germany). Chemiluminescence signals were
indicated as integrated optical density (IOD).
Streptavidin-KRAB was quantiﬁed by incubating cleared
cell lysate (40ml) with 1mg/ml FITC-biotin (60ml) (Fluka,
Buchs, Switzerland, Cat. No. 53608) for 30min before
measuring ﬂuorescence intensity. Fluorescence of
FITC-Biotin bound to streptavidin is quenched and can
be used to quantify streptavidin (50). Fluorescence
quenching is indicated in relative ﬂuorescence units
(RFU). SEAP production was quantiﬁed as detailed
by Schlatter and coworkers (51) In brief, the cell
culture supernatant, collected 48h after seeding/transfec-
tion, was heated to 658C for 30min to inactivate
endogenous phosphatases and then centrifuged for 2min
at 14000 g to remove cell debris. An aliquot of
80ml supernatant were mixed with 100ml SEAP buﬀer
(20mM homoarginine, 1mM MgCl2, 21% (v/v) dietha-
nolamine, pH 9.8) and the reaction was started by
addition of 20ml pNPP (120mM p-nitrophenylphosphate
in SEAP buﬀer) and the light absorbance timecourse
scored at 405nm. SEAP levels were calculated according
to Lambert-Beer’s law using the slope of the timecourse
and the speciﬁc absorption coeﬃcient of the reaction
product p-nitrophenolate ("pNP=18600cm
 1 M
 1).
IFN-b production was proﬁled by ELISA (PBL
Biomedical Laboratories, Piscataway, NJ, USA, Cat.
No. 41400-1A) and the cell number was determined
either by a Casy
TM Counter TTC (Scha ¨ rfe System
GmbH, Reutlingen, Germany) or by using a colorimetric
WST-1-based assay (Roche Applied Science, Rotkreuz,
Switzerland, Cat. No. 11644807001). All experimental
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Bioreactor operation
Cells were cultivated in a BioWave 50SPS bioreactor
(Wave Biotech AG, Tagelswangen, Switzerland)
equipped with Wave Bag 2LOpt for optical pH and
DO control of the 1l culture. The bioreactor was operated
at a rocking rate of 16min
 1, a rocking angle of 58 and an
aeration rate of 50ml/min with inlet gas humidiﬁcation to
prevent evaporation of the medium (HumiCare 200,
Gruendler Medical, Freudenstadt, Germany). Two milli-
liter samples were withdrawn at the indicated points in
time. Samples for assessment of SEAP production were
centrifuged (2min, 14000 g) and the supernatant was
stored at  208C until analysis. Cell density was quantiﬁed
using the colorimetric WST-1 kit (Roche Applied Science,
Rotkreuz, Switzerland, Cat. No. 11644807001).
Animalstudies
CHO-K1 transgenic for pWW938, pWW944, pWW804
and pMF111 were encapsulated in 400mm alginate-PLL
(poly-L-lysine)-alginate beads using the Inotech
Encapsulator Research IE-50R (Inotech Biotechnologies
Ltd., Basel, Switzerland) according to the manufacturer’s
protocol and at the following speciﬁc settings: 0.2mm
nozzle, 20ml syringe at a ﬂow rate of 315 units, nozzle
vibration frequency 1108s
 1, voltage for bead dispersion
800V. Female OF1 (oncins france souche 1) mice were
obtained from Iﬀa-Credo and kept on a biotin-free diet
(Socie ´ te ´ SAFE, Augy, France) for two weeks, whereas the
control mice were fed the same diet supplemented with
4mg/kg biotin. Biotin deﬁciency was monitored using the
forced swim test (52). 700 microliter of ChoMaster HTS
medium containing 50% capsules (2 10
6 cells, 200 cells/
capsule) were injected intraperitoneally into the mice.
When indicated, biotin was dissolved in 0.9% NaCl and
administered by intraperitoneal injection 1h after capsule
implantation. Blood samples were collected retroorbitally
and serum was produced using microtainer SST tubes
(Beckton Dickinson, Franklin Lakes, NJ, USA, Cat. No.
365968). Serum of control mice (implanted with capsules
and kept with or without biotin supplementation) did not
show any detectable SEAP levels. All experiments involv-
ing animals were conducted according to European
Community legislation (86/609/EEC), and have been
approved by the French Republic (No. 69266310) and
performed by M.D-E. at the Institut Universitaire de
Technologie, IUTA, F-69622 Villeurbanne Cedex, France.
Inducers
D(+)-biotin (Acros Organics, Geel, Belgium, Cat. No.
23009) was prepared as a 10mM stock solution in H2O and
was typically used at a ﬁnal concentration of 100nM
unless stated otherwise. At concentrations above 10mM,
biotin was dissolved as stock solution in DMSO. Avidin
(Pierce, Rockford, IL, USA, Cat. No. 21121) was
prepared as a 100  stock solution in phosphate-buﬀered
saline (PBS; 20mM NaH2PO4, 150mM NaCl, pH 7.2).
The concentration of avidin was expressed as
biotin-binding capacity. Tetracycline (Sigma, Cat. No.
T7660) was prepared as a 1mg/ml stock solution in H2O
and used at a ﬁnal concentration of 2mg/ml. For
determination of biotin stability, ChoMaster containing
100mM biotin and 5% FCS was incubated for one week at
378C and biotin samples were quantiﬁed daily using
a HABA (2-(40hydroxyazobenzene) benzoic acid)-based
biotin quantiﬁcation kit (EZ biotin quantiﬁcation kit,
Pierce, Rockford, IL, USA Cat. No. 28005). No signi-
ﬁcant decrease in biotin concentration could be observed.
In pigs, biotin shows a half-life time of up to 22h (53).
RESULTS
Design ofavitamin H-responsive mammalian expression
system
In order to enable precise expression dosing by vitamin H,
we have converted proven tetracycline-responsive expres-
sion system into a vitamin H-adjustable transcription
control modality (Figure 1A). In the presence of biotin
(+Biotin) constitutive expression of the Escherichia coli
biotin ligase BirA [pWW804; PhCMV-BirA-pA; (42,54)]
biotinylates tetracycline- [tTA, TetR-VP16; (19)] depen-
dent transactivators, which have been fused to the
synthetic biotinylation signal (Avitag, AT; (41);
pWW938, PSV40-tTA-AT-pA, Figure 1C-i) thereby pro-
moting biotin (B)-dependent heterodimerization with the
krueppel-associated box protein of the human kox-1 gene
(KRAB; SA-KRAB; pWW944, PSV40-SA-KRAB-pA)
which has been fused to streptavidin (SA) (Figures 1A
and C-ii). Since KRAB-mediated silencing overrides
the VP16-based transactivation capacity of tTA-AT, the
chimeric transrepressor (tTA-TA-B-SA-KRAB) binds and
represses the established tetraycline- (PhCMV  1; pMF111,
PhCMV  1-SEAP-pA) responsive promoter (Figure 1C-iii).
At high biotin concentrations (Figure 1C-iv), all avitag
and streptavidin sites are expected to be saturated by free
biotin thereby competitively inhibiting SA-AT heterodi-
merization and de-repressing target gene expression.
Biotin deprivation (Figure 1C,  Biotin) prevents or
abolishes heterodimerization of chimeric transrepressors
thereby enabling classic tTA-mediated transgene expres-
sion which can be repressed by addition of regulating
tetracycline antibiotics (Figure 1C, +TET) independent
of biotin availability. Expression of all biotin-responsive
regulatory genes has been validated by western blot
analysis or ﬂuorescence quenching (Figure 1B).
Vitamin H-controlled transgeneexpression in mammalian
cell lines
Vitamin H-controlled transgene expression was validated
by co-transfection of CHO-K1 with pWW804 (PhCMV-
BirA-pA), pWW944 (PSV40-SA-KRAB-pA), pWW938
(PSV40-tTA-AT-pA) and pMF111 (PhCMV  1-SEAP-pA)
followed by SEAP quantiﬁcation 48h after cultivation in
the presence or absence of biotin and the regulating
antibiotic tetracycline (Figure 2A). Cells exhibited high-
level SEAP expression in the absence of regulating agents
and repressed transgene expression in the presence of
biotin or tetracycline. The biotin-regulated gene expression
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human embryonic kidney cells (HEK293-T) (Figure 2B)
and both vitamin H and tetracycline could be used to
control the production of the multiple sclerosis therapeutic
beta interferon (IFN-b; pWW732, PhCMV  1-IFN-b-pA)
(Figure 2C).
Speciﬁcity of the biotin-controlled expression system
was assessed by selective omission individual
components including (i) the biotin ligase BirA
(pWW804), (ii) SA-KRAB (pWW944), (iii) BirA and
SA-KRAB (pWW804, pWW944), (iv) BirA, SA-KRAB,
tTA-AT (pWW804, pWW944, pWW938) or (v) by
replacing the avitag-containing tTA-AT (pWW938)
by the original tTA (pSAM200, PSV40-tTA-pA).
Exclusion of either BirA, SA-KRAB or Avitag
abolished biotin-responsive transgene repression while
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Figure 1. Vitamin H-responsive gene expression in mammalian cells. (A) Expression vectors for vitamin H-responsive gene expression. AT, synthetic
BirA-speciﬁc biotinylation signal (Avitag, AT); BirA, Escherichia coli biotin ligase; IFN-b, human beta interferon; PGTX, synthetic promoter; KRAB,
krueppel-associated box protein of the human kox-1 gene; pA, simian virus 40-derived polyadenylation signal; PhCMV  1, tTA-speciﬁc tetracycline-
responsive promoter; PhCMV, human cytomegalovirus immediate early promoter; PSV40, simian virus 40 promoter; SA, streptavidin; SEAP, human
placental secreted alkaline phosphatase; tTA, tetracycline-dependent transactivator. (B) Quantiﬁcation of BirA, tTA-AT and SA-KRAB expression
levels. Cells were transfected with either all three regulatory vectors (pWW804, pWW938 and pWW944) or pTT-Bio alone followed by quantiﬁcation
of the expression levels by chemiluminiscence-based western blot analysis (BirA, tTA-AT) or by incubating SA-KRAB-containing cell lysates with
FITC-biotin, the ﬂuorescence of which is quenched upon binding to streptavidin. The expression levels of the three proteins were also quantiﬁed in
the stable cell line BioCHO-SEAP. IOD, integrated optical density of chemiluminescence signal; RFU, relative ﬂuorescence units. (C) Mode of
function. In the presence of biotin (+Biotin), the avitagged tTA (tTA-AT) is biotinylated by BirA (i) thereby triggering binding of streptavidin-
KRAB [SA-KRAB, (ii)] and silencing of tTA-AT-mediated PhCMV  1 activation (iii). At high biotin concentrations all tTA-AT and SA-KRAB-
binding sites are saturated thereby preventing heterodimerization and de-repression of the target gene (iv). In the absence of biotin ( Biotin)
heterodimerization of tTA-AT and SA-KRAB is prevented and tTA-AT binding to PhCMV  1 induces SEAP expression. In the presence of
tetracycline (+TET), tTA-AT-binding to PhCMV  1 is prevented regardless of whether or not it has heterodimerized with SA-KRAB, and SEAP
expression remains silent. Free standard binding enthalpies (G0) for the covalent biotin-avitag bond as well as for the non-covalent biotin-
streptavidin interaction are indicated.
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(Figure 2D). In the absence of either tTA-AT or tTA no
SEAP expression could be observed indicating that all
components are essential and suﬃcient for biotin-
controlled gene expression (Figure 2D). In all of these
experiments, SEAP production reached identical
maximum levels in the absence of biotin and tetracycline,
indicating that the AVITAG fusion does not impact tTA
function (tTA-AT, pWW938, 2.9 0.3U/l; tTA,
pSAM200, 2.7 0.1U/l).
To provide biotin-controlled gene regulation in a
easy-to-handle two-vector format (19), we have cloned
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triple-transcript expression format, in which the ﬁrst
cistron (SA-KRAB) is transcribed from a simian virus
40 promoter (PSV40) while subsequent cistrons two (tTA-
AT) and three (BirA) are under control of compact
synthetic promoters (PGTX) (47,48) (pTT-Bio; PSV40-SA-
KRAB-PGTX-tTA-AT-PGTX-BirA-pA). Co-transfection
of pTT-Bio with the response vector pMF111 into
CHO-K1 cells resulted in high-level SEAP expression in
the absence of biotin while addition of biotin and/or
tetracycline shut oﬀ SEAP production (Figure 2E).
Adjustability and induction kinetics of thebiotin control
system
Exposure of CHO-K1 containing components mediating
biotin-controlled SEAP expression (pWW938, pWW944,
pWW804 and pMF111) to increasing vitamin H concen-
trations followed by scoring of SEAP production 48h
after transfection revealed adjustability over 2 logs of
biotin concentrations. Maximum SEAP production
occurred below 1nM of biotin and SEAP repression to
background levels occurred at 100nM of biotin
(Figure 3A). Biotin-dependent expression kinetics were
assessed by cultivating CHO-K1 cells transfected with
plasmids pWW938, pWW944, pWW804 and pMF111 for
68h in the presence (100nM) or absence of biotin which
resulted in linear induction proﬁles between 5 and 53h
after transfection (Figure 3B).
Validation of biotin-controlled productprotein secretion
in mice
In order to validate biotin-responsive expression technol-
ogy in a prototype gene therapy scenario, we micro-
encapsulated CHO-K1 engineered for biotin-controlled
production of the human model glycoprotein SEAP into
coherent alginate-poly-L-lysine-alginate capsules and
injected them intraperitoneally into mice kept on a
biotin-free diet. After implantation, the mice were injected
with either biotin (100mg/ml) or doxycycline (100mg/kg)
and the serum levels of SEAP were proﬁled after 48h.
SEAP proﬁles conﬁrmed maximum product protein
production in the absence of biotin and repressed protein
production in the presence of biotin or doxycycline
(Figure 4A). Relative in vivo regulation proﬁles were
similar compared to identical subcultures maintained
in vitro suggesting that the biotin control system retains
its regulation characteristics in vivo (Figure 4B). The
higher basal expression in the presence of doxycycline or
biotin in vivo (Figure 4A) compared to in vitro (Figure 4B)
may result from lower bioavailability of the inducer
in vivo. However, since biotin- and doxycycline-mediated
in vitro and in vivo repression proﬁles are comparable,
the regulation performance of both systems may be
considered equivalent.
Stable CHO-K1 cell derivatives tetra-transgenic for
biotin-responsive transcription-control components
Extensive characterization of the biotin-responsive tran-
scription control system for biopharmaceutical man-
ufacturing requires availability of a stable cell line for
long-term studies. We have therefore constructed a stable
CHO-K1-derived cell line, which is tetratransgenic
for pWW938 (PSV40-tTA-AT-pA), pWW944 (PSV40-SA-
KRAB-pA), pWW804 (PhCMV-BirA-pA) and pMF111
(PhCMV  1-SEAP-pA) and produces SEAP in a biotin and
tetracycline-responsive manner. Five out of 40 stable cell
clones were cultivated for 48h in biotin- and/or
tetracycline-containing medium and proﬁled for SEAP
production. All cell clones showed high SEAP production
when grown in the absence of regulating molecules
( biotin,  tetracycline), while either addition of biotin
or tetracycline abolished SEAP production (Figure 5A).
The diﬀerent expression levels observed for individual cell
clones may result from random chromosomal integration
and transcription-modulating impact of adjacent genetic
elements. Likewise, transgene expression diﬀerences also
exist between stable and transiently transfected popula-
tions, which produce the product protein from expression
vector episomes (55,56). Since BioCHO-SEAP clone no. 1
(BioCHO-SEAP1) showed the best regulation proﬁle it was
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Figure 3. Analysis of vitamin H-responsive transgene expression.
(A) Dose-response characteristics. A total of 30000 CHO-K1 cells
were co-transfected with plasmids pWW944, pWW938, pMF111 and
pWW804 and cultivated for 48h in biotin-free medium supplemented
with increasing biotin concentrations prior to scoring SEAP produc-
tion. (B) Expression kinetics. A total of 30000 CHO-K1 cells were
co-transfected with plasmids pWW944, pWW938, pMF111 and
pWW804 and SEAP production was proﬁled for 68h in the presence
(+) or absence ( ) of biotin (100nM).
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BioCHO-SEAP1 was conﬁrmed by continuous cultivation
of the cell line for 90 days, which did not reveal any
statistically signiﬁcant decrease in SEAP production (day
0, 0.67 0.5U/l; day 90, 0.65 0.6U/l). Biotin-responsive
SEAP production kinetics for which BioCHO-SEAP1 was
seeded in biotin-free or biotin-containing medium (t=0)
revealed a steady increase over time when cultured in the
absence of an inducer, while biotin addition resulted in
background SEAP levels only (Figure 5B). Reversibility of
biotin-responsive gene expression induction was assessed
by cultivating initial BioCHO-SEAP1 populations in either
biotin-free or biotin-containing medium. After 31 and
100h of cultivation, the cell population was split and the
biotin status maintained or reversed as indicated.
Sequential induction and repression of SEAP production
was followed over a one-week period (Figure 5C). Biotin-
controlled SEAP expression was reversible and the
induction or repression kinetics were not inﬂuenced by
the biotin cultivation history of the BioCHO-SEAP
population (Figure 5C). The dose-response proﬁles
recorded over 7 biotin concentration logs revealed
unique expression characteristics: (i) gradual ON-to-
OFF expression proﬁles between 1 and 100nM, reﬂecting
increasing heterodimerization of transsilencer and transsi-
lencer-mediated repression of tTA-AT-driven PhCMV  1
transcription. (ii) Full OFF state at biotin concentrations
ranging from 100 to 1000nM, reﬂecting maximum
transsilencing capacity. (iii) graded OFF-to-ON expres-
sion at biotin levels above 100mM, suggesting that free
biotin levels exceeding the ligation capacity of BirA may
bind and sequestrate SA-KRAB thereby competitively
inhibiting its heterodimerization with biotinylated
tTA-AT (Figure 5D).
Biotin-inducibleexpressioninbiotin-containingenvironments
While all aforementioned experiments were conducted
in biotin-free medium, standard cell culture media and
serum additives contain biotin at an average level of
50nM which fully represses the biotin control system
(Figure 5D). Dose-response characteristics of BioCHO-
SEAP1 cultivated in standard serum-containing cell
culture medium and exposed to increasing biotin concen-
trations resulted in a gradual increase in SEAP produc-
tion, conﬁrming that the biotin control modality operates
as an inducible expression system under standard culture
conditions (Figure 6A). Furthermore, expression kinetics
in the presence of 2000mM biotin increased steadily,
whereas the absence of additional biotin resulted in
background expression only (Figure 6B).
A further strategy to induce the biotin control system is
to sequester repressing biotin in standard medium by
addition of avidin. Cultivation of BioCHO-SEAP1 in the
presence of increasing avidin concentrations resulted in a
gradual increase in SEAP production, thereby enabling
adjustable transgene expression by administration of an
exogenous protein (Figure 6C). Expression kinetics in the
presence or absence of avidin increased steadily over time
(Figure 6D). However, the overall regulation performance
using avidin as an inducer was lower compared to biotin-
triggered expression control (Figure 6A and C), suggesting
that avidin is unable to fully compete with the thermo-
dynamically favored enzymatic biotinylation of tTA-AT.
Biotin-inducible proteinproduction in aprototype
biopharmaceutical manufacturing scenario
Despite intensive research no signiﬁcant side eﬀects have
been discovered for biotin, neither following oral uptake
nor after injection (57). Therefore, this FDA-licensed
molecule represents an ideal inducer for any bioprocess
application requiring precisely timed expression control
(11,12,58). We have therefore evaluated the compatibility
of vitamin H-responsive gene expression with standard
bioreactor operation by cultivating BioCHO-SEAP1 for
53h in a BioWave bioreactor using 1l of standard biotin-
containing (non-supplemented) culture medium before
adding 2mM biotin to trigger SEAP production. While
BioCHO-SEAP1 grew exponentially during the entire
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Figure 4. In vivo validation of vitamin H-responsive gene expression.
(A) CHO-K1 cells were co-transfected with plasmids pWW944,
pWW938, pMF111 and pWW804, encapsulated in coherent alginate-
poly-L-lysine-alginate capsules and intraperitoneally injected into
biotin-deﬁcient mice (2 10
6 cells/mouse). Mice further received
biotin (+Biotin, 100mg/kg) or doxycycline (+DOX, 100mg/kg)
injections and were subsequently kept for 48h prior to quantiﬁcation
of SEAP production in the serum. (B) Parallel in vitro validation.
Encapsulated CHO-K1 cells co-transfected with plasmids pWW944,
pWW938, pMF111 and pWW804 were cultivated in vitro (2 10
6 cells/
20ml biotin-free medium) in the presence of exogenous biotin
(+Biotin, 100nM) or doxycycline (+DOX, 2mg/ml) for 48h prior to
quantiﬁcation of SEAP production.
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after addition of biotin, thereby validating the suitability
for timely controlled biotin-responsive gene expression in
a prototype biopharmaceutical manufacturing scenario
(Figure 7).
DISCUSSION
Adjustable transgene expression technology is fundamen-
tal to prototype gene therapy scenarios (6,7,59–61),
functional genomic research (14,16), synthetic biology
(1–3,62) and forefront biopharmaceutical manufacturing
strategies (11,12,58,63). The novel vitamin H-responsive
expression technology exhibits several advantages regard-
ing standard operation and regulation performance
compared to established systems which are typically
triggered by side-eﬀect-prone immunosuppressants, hor-
mones or antibiotics (32,34,35,37,38): Vitamin H (biotin)
is the ﬁrst inducing agent with no or only low known side
eﬀects (e.g. to our knowledge, no LD50 has ever been
described). As biotin is a natural component of cell culture
media, its removal or supplementation to native levels is
not expected to require additional validation or licensing
eﬀorts for biopharmaceutical manufacturing as would be
the case for pharmacologically active inducers such as
hormones, immunosupressors and antibiotics.
When comparing biotin-adjustable regulation charac-
teristics to classic expression systems, biotin-adjustable
transgene control exhibits unique band pass ﬁlter-
like expression characteristics using a single inducer
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PAGE 9 OF 13 Nucleic Acids Research, 2007, Vol. 35,No. 17 e116molecule: (i) within the low biotin concentration window
(0–2nM), transcription is fully induced, (ii) it is maximally
repressed between 100 and 1000nM biotin and (iii) again
entirely turned on beyond 100mM. This exclusive feature
enables sequential induction, repression and re-induction
using increasing doses of vitamin H, an expression pattern
which has so far only been achieved in bacteria using
a sophisticated gene network (64). The unique biotin-
dependent band pass ﬁlter characteristic could be
explained by a competition of tTA-AT and SA-KRAB
for free biotin. At low biotin concentrations (0–100nM),
binding of biotin to tTA-AT [via the intermediate
biotin–BirA complex, (65)] is thermodynamically favored
[G0= 360kJ/mol for an amide bond (in trans) versus
G0= 80kJ/mol for the non-covalent binding of biotin
to SA-KRAB (66,67)], resulting in biotinylated tTA-AT
and subsequent transcriptional shutdown after binding to
SA-KRAB. At high biotin concentrations (4100mM) free
biotin is expected to saturate all tTA-AT and SA-KRAB
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biotinylated tTA-AT. While basic research scientists may
appreciate the extended regulation bandwidth emulating
developmental expression patterns (64,68–70), the bio-
pharmaceutical manufacturing could welcome the ﬁrst
opportunity to reverse the expression state of diﬃcult-
to-produce protein therapeutics without media exchanges
and ﬁltration operations.
Owing to the use of TetR as the DNA-binding
component, the biotin-responsive gene expression tech-
nology is compatible with standard tetracycline-
responsive promoters, established cell lines and mouse
strains (15,19,20,59) and is unique in integrating two input
signals: biotin and tetracycline. This dual-input sensitivity
permits override of the biotin-controlled transgene expres-
sion by administration of tetracycline which may represent
a useful safety feature in future cell engineering strategies.
Since biotin is a physiological component the synthetic
control modality may be used to convert endogenous
biotin concentrations into a therapeutic transgene
response. Scenarios to treat biotinidase-associated meta-
bolic disorders by triggering therapeutic biotinidase
expression at low pathologic biotin concentrations and
shutting it oﬀ when physiologic biotin concentrations
are reached, could now become a reality (71–73). Despite
the ubiquitous presence of biotin in living systems,
interference-free transgene control can still be achieved
by (i) addition of biotin-sequestrating avidin or by
(ii) administration of excess biotin (41000nM) thereby
taking advantage of the high-biotin regulation window of
the aforementioned band-pass ﬁlter.
Considering all of the design and performance char-
acteristics in mammalian cells, mice as well as during
standard bioreactor operation, we are convinced that
biotin-controlled transgene expression will foster advances
in basic research, gene therapy scenarios as well as in
biopharmaceutical manufacturing.
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